Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

29.94 -0.57 (-1.87%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

2 Healthcare Stocks Wall Street Analysts Say Could Rally 60% or More ↗

March 31, 2026

There are some tempting bargains if you know where to look.

Via The Motley Fool

1 Reason This Biotech Stock Could Triple Before Year-End ↗

March 29, 2026

This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate.

Via The Motley Fool

Why Viking Therapeutics Stock Could Take Off Later This Year ↗

March 23, 2026

Some key clinical trial data is expected soon.

Via The Motley Fool

Goldman Sachs Bullish Forecast: 15% Increase in 2026 U.S. M&A Activity

March 23, 2026

As the first quarter of 2026 comes to a close, the financial world is buzzing with a renewed sense of optimism. Goldman Sachs (NYSE: GS) has released its highly anticipated 2026 Global M&A Outlook,...

Via MarketMinute

Small-Cap Resilience: Russell 2000 Surges 3% as Geopolitical Tensions Ease and ‘Risk-On’ Appetite Returns

March 23, 2026

On March 23, 2026, the small-cap heavy Russell 2000 Index surged by a definitive 3.0%, soundly outperforming the S&P 500 and the Nasdaq Composite in a session characterized by aggressive "risk-on"...

Via MarketMinute

Topics ETFs Economy Stocks

Got $1,500? Is It Better to Buy Bitcoin, or Viking Therapeutics? ↗

March 22, 2026

One of these assets is catalyst-driven; the other isn't.

Via The Motley Fool

Topics Intellectual Property

Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics ↗

March 17, 2026

Each of these companies could benefit from this high-growth market over time.

Via The Motley Fool

What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗

March 16, 2026

Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

3 Companies at the Forefront of the GLP-1 Pill Wars ↗

March 16, 2026

Via MarketBeat

Here's Why Viking Therapeutics Stock Recovered and Can Soar 2026 ↗

March 11, 2026

The company is pursuing a Phase 3 trial in its most exciting pipeline drug, and investors are awaiting potentially exciting data by the end of September.

Via The Motley Fool

VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race ↗

March 11, 2026

Viking says it needs only about 5%-10% market share to succeed in the obesity market, despite competition from Eli Lilly and Novo Nordisk.

Via Stocktwits

The Great Rotation: Russell 2000 Surges as Investors Flee Overstretched Tech Giants

March 10, 2026

NEW YORK — In a dramatic shift of market leadership, the Russell 2000 index (INDEXRUSSELL:RUT) continued its historic outperformance on Tuesday, March 10, 2026, as investors aggressively rotated...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy ETFs

Viking CEO Sees Its Obesity Drug Beating Novo's Wegovy In Weight Loss ↗

March 10, 2026

As per the CEO, the company will have four late-stage trials by the end of 2026.

Via Stocktwits

The $1.35 Trillion Wall: Why Small-Caps are Faltering as the S&P 500 Defies Gravity

March 09, 2026

As of March 9, 2026, the long-predicted "reckoning" for American small-cap stocks has officially arrived. While the broader market remains buoyed by the resilient "Magnificent Seven" and a robust AI...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Forget AI Stocks: This Potentially Disruptive Biotech Could Soar By 181%, According to Wall Street ↗

March 09, 2026

This stock could make you a fortune in the next two years, or lose you a whole lot of money.

Via The Motley Fool

Topics Artificial Intelligence

The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026

February 27, 2026

As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the...

Via Finterra

Topics Economy Intellectual Property

Viking Therapeutics: The High-Stakes Weight Loss Contender ↗

February 26, 2026

Via MarketBeat

Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗

February 25, 2026

Eli Lilly has seen revenue and earnings soar in recent years.

Via The Motley Fool

Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making. ↗

February 23, 2026

Is this the best way to cash in on the weight-loss gold rush?

Via The Motley Fool

Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial

February 23, 2026

The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a...

Via MarketMinute

Why Viking Therapeutics Stock Is Up More Than 9% Today ↗

February 23, 2026

A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow.

Via The Motley Fool

Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head

February 23, 2026

Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing...

Via MarketMinute

Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial

February 23, 2026

COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated...

Via MarketMinute

Topics Earnings

3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds ↗

February 23, 2026

Viking stock has plenty of room to run.

Via The Motley Fool

2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗

February 19, 2026

These biotech companies have catalysts ahead.

Via The Motley Fool

Is Viking Therapeutics Stock Really Going to $125? ↗

February 19, 2026

Never say never. There's certainly a mathematical path to that level, if the company navigates it correctly.

Via The Motley Fool

The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth

February 17, 2026

In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion...

Via MarketMinute

Topics Earnings Economy

2026 Could Be a Big Year for Viking Therapeutics. Time to Buy? ↗

February 17, 2026

Viking should have plenty of news to share with investors this year.

Via The Motley Fool

The Great Rotation: Russell 2000 Rockets 18% as Cooling Inflation Sparks Historic Small-Cap Surge

February 13, 2026

The financial landscape shifted violently this week as the long-dormant Russell 2000 index (INDEXRUSSELL:RUT) staged a breathtaking 18% rally, marking its best single-week performance in decades....

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Small Caps Roar: Russell 2000 Surges as Cooling Inflation Ignites Rate Cut Hopes

February 13, 2026

In a decisive shift for equity markets, the small-cap heavy Russell 2000 index outperformed its large-cap peers on Friday, February 13, 2026, as investors cheered a cooler-than-expected Consumer Price...

Via MarketMinute

Topics Bonds ETFs Economy

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.